ArticleFrontiers in nutrition2026
A LODDS and PNI-based personalized prognostic model for patients with gastric cancer receiving neoadjuvant chemotherapy.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to develop and validate a risk stratification model incorporating the log odds of positive lymph nodes (LODDS) and the prognostic nutritional index (PNI) to predict outcomes in patients with locally advanced gastric cancer (LAGC) undergoing neoadjuvant chemotherapy (NAC). Methods: A retrospective cohort of patients with NAC-LAGC who underwent radical gastrectomy between January 2016 and January 2025 was enrolled. The cohort was randomly split into a training set and a validation set at a 7:3 ratio. Independent risk factors were identified through univariable and multivariable Cox regression analyses in the training set. An individualized nomogram for progression-free survival (PFS) and a risk stratification model were subsequently developed. Model performance was evaluated using the area under the receiver operating characteristic (ROC) curve (AUC), calibration curves, and decision curve analysis (DCA), and was further validated in the validation set. Results: A total of 450 patients were included. In the training set, 255 (79.2%) were male, and 67 (20.8%) were female; 96 (29.8%) were under 60 years, and 226 (70.2%) were 60 years or older. Multivariable analysis identified LODDS, PNI, age, tumor regression grade (TRG), and ypT stage as independent risk factors for PFS. The nomogram based on LODDS outperformed the ypN stage-based nomogram (AUCs at 3, 4, and 5 years: 0.916 vs. 0.888, 0.917 vs. 0.867, and 0.935 vs. 0.876, respectively; all Conclusion: The LTTAP model integrating LODDS and PNI offers strong prognostic value for patients with NAC-LAGC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.